MCID: EYD001
MIFTS: 30

Eye Degenerative Disease malady

Categories: Neuronal diseases, Eye diseases

Aliases & Classifications for Eye Degenerative Disease

Aliases & Descriptions for Eye Degenerative Disease:

Name: Eye Degenerative Disease 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:9799
ICD10 33 H44.30 H44.5
UMLS 69 C0154777

Summaries for Eye Degenerative Disease

MalaCards based summary : Eye Degenerative Disease is related to proximal myopathy and ophthalmoplegia and plantar nerve lesion. An important gene associated with Eye Degenerative Disease is KCNJ13 (Potassium Voltage-Gated Channel Subfamily J Member 13), and among its related pathways/superpathways is Metabolism of fat-soluble vitamins. The drugs Dexamethasone and Diclofenac have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are nervous system and vision/eye

Related Diseases for Eye Degenerative Disease

Diseases related to Eye Degenerative Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
id Related Disease Score Top Affiliating Genes
1 proximal myopathy and ophthalmoplegia 10.2 GUCA1A GUCY2D
2 plantar nerve lesion 10.2 COL2A1 KCNJ13
3 arthrogryposis, distal, type 2a 10.2 GUCA1A GUCY2D
4 moyamoya disease 10.2 COL2A1 KCNJ13
5 warm antibody hemolytic anemia 10.2 COL2A1 KCNJ13
6 ureter cancer 10.2 COL2A1 KCNJ13
7 adult-onset still's disease 10.1 COL2A1 KCNJ13
8 blessig's cysts 10.1 COL2A1 PRPH2
9 partial central choroid dystrophy 10.1 GUCA1A GUCY2D PRPH2
10 monofixation syndrome 10.1 GUCA1A GUCY2D PRPH2
11 van buchem disease 10.1 GUCA1A GUCY2D PRPH2
12 hypertrichosis terminalis, generalized, with or without gingival hyperplasia 10.1 GUCY2D PRPH2
13 polyhydramnios 10.1 GUCA1A GUCY2D PRPH2
14 breast osteosarcoma 10.0 FZD4 NDP
15 glioblastoma classical subtype 10.0 GUCA1A GUCY2D
16 smed strudwick type 10.0 COL2A1 NDP
17 van buchem disease, type 2 10.0 FZD4 NDP
18 biemond syndrome ii 10.0 FZD4 NDP
19 visual epilepsy 10.0 GJD2 ZNF644
20 epileptic encephalopathy, early infantile, 1 10.0 COL2A1 NDP
21 cornea plana 10.0 FZD4 NDP
22 liver cirrhosis 10.0 GUCA1A GUCY2D KCNJ13 PRPH2
23 astigmatism 10.0 FZD4 NDP
24 refractive error 9.9 CYP4V2 GUCA1A GUCY2D PRPH2
25 vernal conjunctivitis 9.9 FZD4 NDP
26 adult liposarcoma 9.9 GUCA1A GUCY2D NDP PRPH2
27 nystagmus 5, congenital, x-linked 9.8 FZD4 NDP
28 anterograde amnesia 9.7 COL2A1 FZD4 KCNJ13 NDP
29 neonatal abstinence syndrome 8.7 COL2A1 CYP4V2 FZD4 GJD2 GUCA1A GUCY2D

Graphical network of the top 20 diseases related to Eye Degenerative Disease:



Diseases related to Eye Degenerative Disease

Symptoms & Phenotypes for Eye Degenerative Disease

MGI Mouse Phenotypes related to Eye Degenerative Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.5 COL2A1 FZD4 GJD2 GUCA1A GUCY2D NDP
2 vision/eye MP:0005391 9.23 COL2A1 CYP4V2 FZD4 GJD2 GUCA1A GUCY2D

Drugs & Therapeutics for Eye Degenerative Disease

Drugs for Eye Degenerative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 464)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
2
Diclofenac Approved, Vet_approved Phase 4,Phase 1 15307-86-5 3033
3
Ephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 299-42-3 9294
4
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
5
Dorzolamide Approved Phase 4,Phase 2,Phase 3 120279-96-1 3154 5284549
6
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129497-78-5
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
8
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 90-82-4 7028
9
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 347396-82-1 459903
10
Nepafenac Approved Phase 4,Phase 3,Phase 2 78281-72-8 151075
11
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 67-73-2 6215
12
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
13
Temazepam Approved Phase 4,Phase 3 846-50-4 5391
14
Povidone-iodine Approved Phase 4,Phase 3,Phase 2,Phase 1 25655-41-8
15
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
16
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
17
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
18
Copper Approved Phase 4 15158-11-9, 7440-50-8 27099
19
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
20
Timolol Approved Phase 4,Phase 2,Phase 3 26839-75-8 33624 5478
21
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
22
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
23
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
24
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
25
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
26
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
27
Menthol Approved Phase 4 2216-51-5 16666
28
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
30
Difluprednate Approved Phase 4 23674-86-4 443936
31
Travoprost Approved Phase 4 157283-68-6 5282226
32
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
33
Glimepiride Approved Phase 4 93479-97-1 3476
34
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
35
Eplerenone Approved Phase 4,Phase 2,Phase 3 107724-20-9 150310 443872
36
Acetylcholine Approved Phase 4 51-84-3 187
37
Rasagiline Approved Phase 4 136236-51-6 3052776
38
Empagliflozin Approved Phase 4 864070-44-0
39
Riboflavin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 83-88-5 493570
40
Vitamin C Approved, Nutraceutical Phase 4,Phase 3 50-81-7 5785 54670067
41
Lutein Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 127-40-2 6433159 5368396
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 59-30-3 6037
43
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1 59-02-9 14985
44
Choline Approved, Nutraceutical Phase 4,Phase 2 62-49-7 305
45
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 11103-57-4, 68-26-8 445354
46
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 58-05-9 54575, 6560146 143
47 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
48
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2,Phase 1 91714-94-2 60726
49
Maleic acid Experimental Phase 4 110-16-7 444266
50 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 1616)
id Name Status NCT ID Phase
1 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4
2 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4
3 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
4 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
5 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4
6 Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor Unknown status NCT01896284 Phase 4
7 A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Unknown status NCT00354445 Phase 4
8 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4
9 The Endurance 1 Trial Unknown status NCT02297204 Phase 4
10 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4
11 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4
12 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4
13 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4
14 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4
15 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4
16 Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye Completed NCT01986907 Phase 4
17 Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment Completed NCT00680498 Phase 4
18 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4
19 Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept Completed NCT02125864 Phase 4
20 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed NCT01006538 Phase 4
21 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4
22 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Completed NCT00324116 Phase 4
23 FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4
24 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
25 A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) Completed NCT01542866 Phase 4
26 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) Completed NCT01722045 Phase 4
27 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4
28 Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab Completed NCT02309281 Phase 4
29 Study for Recalcitrant Age Related Macular Degeneration Completed NCT01543568 Phase 4
30 Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. Completed NCT01846273 Phase 4
31 Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4
32 UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) Completed NCT01988662 Phase 4
33 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
34 Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing Completed NCT01453920 Phase 4
35 Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) Completed NCT02142296 Phase 4
36 Combined Therapy in Age-Related Macular Degeneration (ARMD) Completed NCT00805649 Phase 4
37 Study EvAluating Genotypes While Using Lucentis 2 Completed NCT01464723 Phase 4
38 LUCAS (Lucentis Compared to Avastin Study) Completed NCT01127360 Phase 4
39 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4
40 Size Progression of Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
41 Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment Completed NCT01722656 Phase 4
42 Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments Completed NCT00976222 Phase 4
43 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4
44 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4
45 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4
46 Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration Completed NCT00556348 Phase 4
47 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed NCT01775124 Phase 4
48 Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Completed NCT01244334 Phase 4
49 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT00674323 Phase 4
50 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4

Search NIH Clinical Center for Eye Degenerative Disease

Genetic Tests for Eye Degenerative Disease

Anatomical Context for Eye Degenerative Disease

MalaCards organs/tissues related to Eye Degenerative Disease:

39
Eye

Publications for Eye Degenerative Disease

Variations for Eye Degenerative Disease

Expression for Eye Degenerative Disease

Search GEO for disease gene expression data for Eye Degenerative Disease.

Pathways for Eye Degenerative Disease

Pathways related to Eye Degenerative Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.13 CYP4V2 GUCA1A GUCY2D

GO Terms for Eye Degenerative Disease

Cellular components related to Eye Degenerative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 photoreceptor outer segment GO:0001750 8.96 GUCA1A PRPH2
2 photoreceptor disc membrane GO:0097381 8.62 GUCA1A GUCY2D

Biological processes related to Eye Degenerative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.62 CYP4V2 GUCA1A GUCY2D NDP
2 sensory perception of sound GO:0007605 9.43 COL2A1 FZD4 NDP
3 regulation of rhodopsin mediated signaling pathway GO:0022400 9.37 GUCA1A GUCY2D
4 visual perception GO:0007601 9.17 COL2A1 CYP4V2 GJD2 GUCA1A GUCY2D NDP
5 retina vasculature morphogenesis in camera-type eye GO:0061299 9.16 FZD4 NDP
6 extracellular matrix-cell signaling GO:0035426 8.96 FZD4 NDP

Sources for Eye Degenerative Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....